Alan H. Auerbach
Chairman and Chief Executive, Puma Biotechnology
Alan H. Auerbach has served as chairman, chief executive, and president of Puma Biotechnology since its inception. Prior to founding Puma, he served as founder, chief executive, president, and board member of Cougar Biotechnology Inc. from the company’s inception in 2003 until its acquisition by Johnson & Johnson in July 2009. Prior to founding Cougar, Auerbach was a vice president and senior research analyst from June 1998 to April 2003 at Wells Fargo Securities, where he was responsible for research coverage of small and middle capitalization biotech companies, with a focus on companies in the field of oncology.
Enjoy most: What I do has the potential to make a difference in cancer patients’ lives.
Toughest challenge: Running my previous company, Cougar Biotechnology, during the financial crisis.
Proudest moment: When Zytiga (abiraterone acetate) was approved by the Food and Drug Administration for treating prostate cancer.
Most excited: The outlook for the treatment of cancer is particularly promising at this time.
Fun fact: I have surfed every island in Hawaii.
Alma Maters: Bachelor’s, Boston University; Master’s, University of Southern California.
Favorite destination: Hawaii.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Alan H. Auerbach
- Cancer Drug Developer Puma Completes Funding Round
- ALAN AUERBACH
- Puma Biotechnology to Begin Trading Shares
- Wealthiest Angelenos: 47, Alan Auerbach
- Positive Drug Trials Spur Healthy Investor Interest
- Investors Take Notice of Cancer Drug Company
- Maker of Cancer Drug Passes Test With Investors